<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03095001</url>
  </required_header>
  <id_info>
    <org_study_id>Intraperitoneal bev</org_study_id>
    <nct_id>NCT03095001</nct_id>
  </id_info>
  <brief_title>Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion</brief_title>
  <official_title>Chinese PLA Generation Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Malignant peritoneal adhesion is a common complication and prognostic factor of
      ovarian cancer and other primary abdominal tumors. The incidence of peritoneal adhesion in
      advanced primary peritoneal tumor is 32-56%, which has increased by more than 10 times in the
      recent decade. Malignant peritoneal adhesion is closely associated with the morbidity and
      mortality of malignant intestinal obstruction. The peritoneal adhesion may aggravates the
      abdominal symptoms and reduce quality of life. Further, the peritoneal adhesion may impede
      treatment of primary tumor, such as operation or chemotherapy, lead to a poor prognosis.

      Objective: This study aims to treat malignant peritoneal adhesion with the combination of
      antiangiogenic agent and chemotherapy, evaluate the efficacy and safety of intraperitoneal
      antiangiogenic agent plus chemotherapy. As explosive endpoints, we will examination the
      expression of VEGF-A in peritoneal cavity during the treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peritoneal adhesion ORR (pORR)</measure>
    <time_frame>3weeks after the last treatment</time_frame>
    <description>Degree of adhesion was measured according to NAIR's criteria by laparoscopy. Grade 0 corresponded to no adhesions, Grade 1 and 2 corresponded to filmy adhesions and grade 3 and 4 to dense adhesions. No adhesions is defined as CR, dense adhesions change to filmy adhesions is defined as PR. The total efficiency ORR was calculated by taking the sum of CR+PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Adverse Events</measure>
    <time_frame>From first dose up to 1 month after the last treatment</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>From first dose up to 1 year</time_frame>
    <description>Quality of Life (QoL) assessed by FACT-O</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>From randomization until documented progressive disease or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>From randomization until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The proportion of patients that have a best overall response of complete response (CR) or partial response (PR), as assessed by RECIST 1.1.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Expression of VEGF-A in peritoneal cavity</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Quantitation of VEGF-A by enzyme-linked immunosorbent assay (ELISA), before and after intraperitoneal administration.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Peritoneal Adhesion</condition>
  <arm_group>
    <arm_group_label>Intraperitoneal bevacizumab+ carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraperitoneal administration: intraperitoneal bevacizumab plus carboplatin every 3 weeks for 4-6 cycles
Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intraperitoneal carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraperitoneal administration: intraperitoneal carboplatin every 3 weeks
Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 5mg/kg intraperitoneal administration every 3 weeks for 4-6 cycles</description>
    <arm_group_label>Intraperitoneal bevacizumab+ carboplatin</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>carboplatin AUC=5 intraperitoneal administration every 3 weeks 4-6 cycles</description>
    <arm_group_label>Intraperitoneal bevacizumab+ carboplatin</arm_group_label>
    <arm_group_label>Intraperitoneal carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>paclitaxel 175mg/m2, iv d1, every 3 weeks for 4-6 cycles</description>
    <arm_group_label>Intraperitoneal bevacizumab+ carboplatin</arm_group_label>
    <arm_group_label>Intraperitoneal carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically and radiologically confirmed stage IV or postoperative recurrence
             ovarian cancer.

          2. Age of 18-70, Karnofsky score higher than 80.

          3. No severe functional damage of major organ, normal liver and kidney function.

          4. Peritoneal adhesion. (1) peritoneal adhesions diagnosed by microlaparoscopy or
             abdominal operations, and classification according to Nair criteria is performed. (1)
             must be met. (2) Peritoneal adhesion symptoms, intermittent abdominal pain, abdominal
             distension, nausea and vomiting, hard to pass stools or gas; (3) Peritoneal adhesion
             signsï¼Œabdominal distension, abdominal tenderness, reduced or absent bowel sounds; (4)
             B ultrasound or CT or MRI show peritoneal adhesion or adhesion-related complications.

        Exclusion Criteria:

          1. Complete intestinal obstruction and suitable for surgery.

          2. Patients known to be allergic to bevacizumab or any of the components of the drug.

          3. Other ongoing anti-tumor treatment.

          4. Heart disease with significant clinical symptoms, such as: congestive heart failure,
             coronary heart disease with symptom, arrhythmia hardly be controlled by drugs,
             myocardial infarction in 6 months, or heart failure

          5. Active wound infection and a history of uncontrolled psychiatric illness.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nan Du, PhD</last_name>
    <role>Study Director</role>
    <affiliation>PLA 304 hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nan Du, PhD</last_name>
    <email>dunan304@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Affiliated Hospital, Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100048</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Zhao, Phd</last_name>
    </contact>
    <investigator>
      <last_name>Nan Du, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>DuNan</investigator_full_name>
    <investigator_title>Director of oncology</investigator_title>
  </responsible_party>
  <keyword>bevacizumab</keyword>
  <keyword>Intraperitoneal administration</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Peritoneal Adhesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

